Summary of patient characteristics
| Characteristic . | No. . | % . |
|---|---|---|
| Age, y | ||
| 0-1 | 1 | 2 |
| 1-10 | 38 | 75 |
| > 10 | 12 | 24 |
| Initial WBC count | ||
| < 50 000 | 38 | 75 |
| > 50 000 | 13 | 25 |
| NCI risk group | ||
| Standard risk | 33 | 65 |
| High risk | 15 | 29 |
| Very high risk | 2 | 4 |
| Infant leukemia | 1 | 2 |
| Cytogenetics | ||
| TEL-AML | 15* | 29 |
| Hyperdiploid without trisomy 4, 10, and 17 | 10 | 20 |
| Hyperdiploid with trisomy 4, 10, and 17 | 7* | 14 |
| MLL-rearranged | 1 | 2 |
| Philadelphia chromosome | 2 | 4 |
| Other | 10 | 20 |
| Normal | 6 | 12 |
| Not done | 1 | 2 |
| CNS stage | ||
| 1 | 38 | 75 |
| 2 | 12 | 24 |
| 3 | 1 | 2 |
| End of induction MRD | ||
| < 0.1% | 36 | 71 |
| > 0.1% < 1% | 4 | 8 |
| > 1% | 4 | 8 |
| Not done | 7 | 14 |
| Current disease status | ||
| Relapse | 5 | 10 |
| Continuous remission | 46 | 90 |
| Characteristic . | No. . | % . |
|---|---|---|
| Age, y | ||
| 0-1 | 1 | 2 |
| 1-10 | 38 | 75 |
| > 10 | 12 | 24 |
| Initial WBC count | ||
| < 50 000 | 38 | 75 |
| > 50 000 | 13 | 25 |
| NCI risk group | ||
| Standard risk | 33 | 65 |
| High risk | 15 | 29 |
| Very high risk | 2 | 4 |
| Infant leukemia | 1 | 2 |
| Cytogenetics | ||
| TEL-AML | 15* | 29 |
| Hyperdiploid without trisomy 4, 10, and 17 | 10 | 20 |
| Hyperdiploid with trisomy 4, 10, and 17 | 7* | 14 |
| MLL-rearranged | 1 | 2 |
| Philadelphia chromosome | 2 | 4 |
| Other | 10 | 20 |
| Normal | 6 | 12 |
| Not done | 1 | 2 |
| CNS stage | ||
| 1 | 38 | 75 |
| 2 | 12 | 24 |
| 3 | 1 | 2 |
| End of induction MRD | ||
| < 0.1% | 36 | 71 |
| > 0.1% < 1% | 4 | 8 |
| > 1% | 4 | 8 |
| Not done | 7 | 14 |
| Current disease status | ||
| Relapse | 5 | 10 |
| Continuous remission | 46 | 90 |
Sample 8 had both TEL-AML and hyperdiploid with trisomy 4, 10, and 17.